Vascepa is a prescription medication that contains icosapent ethyl, which is a type of omega-3 fatty acid. It is used to lower high levels of triglycerides in the blood, which can lead to cardiovascular disease. According to Drug Patent Watch [1], Vascepa was approved by the FDA in 2012, and its patent is set to expire in 2030.

Healthline [2] explains that Vascepa has been shown to be effective in reducing triglyceride levels in the blood. In a clinical trial, patients who took Vascepa had a 25% reduction in triglyceride levels after 12 weeks of treatment. Additionally, Vascepa has been shown to have anti-inflammatory effects and may help to reduce the risk of cardiovascular events such as heart attack and stroke.

Medical News Today [3] reports that a study published in the New England Journal of Medicine found that Vascepa reduced the risk of cardiovascular events by 25% in patients with high triglyceride levels. The study followed patients for an average of 4.9 years and found that Vascepa was well-tolerated and did not increase the risk of adverse events.

In terms of long-term use, Healthline [2] notes that there is limited data on the safety and effectiveness of Vascepa beyond 5 years. However, the drug has been shown to be well-tolerated in clinical trials and has not been associated with any serious long-term side effects.

In conclusion, Vascepa has been shown to be effective in reducing triglyceride levels and may help to reduce the risk of cardiovascular events. While there is limited data on the long-term safety and effectiveness of the drug, it has been well-tolerated in clinical trials and has not been associated with any serious long-term side effects.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.healthline.com/health/drugs/vascepa
[3] https://www.medicalnewstoday.com/articles/drugs-vascepa